USANA Health Sciences, Inc. (USNA) Income Statement
USNA 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsUSNA revenue and net income
Where USNA's revenue goes
2025Each bar shows an amount and its share of revenue. USNA kept 1.2% of revenue as net income.
USNA profit margins
USNA growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +8.3% | −2.5% | −4.0% | +0.1% |
| Gross profit | +6.7% | −3.4% | −4.8% | −0.5% |
| Operating income | −23.3% | −22.1% | −22.0% | −9.7% |
| Net income | −74.4% | −46.3% | −38.7% | −19.5% |
| EPS (diluted) | −26.2% | −18.8% | −20.0% | −6.1% |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
USNA quarterly EPS vs estimates
USANA Health Sciences beat the analyst EPS estimate in 7 of the last 8 quarters. Next report: November 3, 2026 (estimate $0.11).
USNA income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $925.3M | $854.5M | $921.0M | $998.6M | $1.19B | $1.13B | $1.06B | $1.19B | $1.05B | $1.01B |
| Cost of revenue | $200.9M | $175.8M | $189.4M | $193.9M | $217.9M | $209.1M | $187.5M | $200.7M | $179.4M | $180.2M |
| Gross profit | $724.4M | $678.8M | $731.6M | $804.7M | $968.6M | $925.5M | $873.4M | $988.5M | $867.9M | $825.9M |
| Research & development | — | $11.6M | $11.4M | $11.6M | $11.1M | $10.6M | $10.3M | $8.8M | $9.0M | $8.8M |
| Sales, general & admin | $337.4M | $258.3M | $257.0M | $697.1M | $798.4M | $749.0M | $727.2M | $800.2M | $735.4M | $687.3M |
| Total operating expenses | $673.5M | $612.4M | $638.5M | $697.1M | $798.4M | $749.0M | $727.2M | $800.2M | $735.4M | $687.3M |
| Operating income | $50.9M | $66.3M | $93.1M | $107.6M | $170.2M | $176.5M | $146.2M | $188.4M | $132.5M | $138.6M |
| Interest income | $2.4M | $11.3M | $8.2M | $3.8M | $2.5M | $2.5M | $4.7M | $4.4M | $2.2M | $1.5M |
| Interest expense | $842,000 | $281,000 | $262,000 | $192,000 | $57,000 | $507,000 | $66,000 | $36,000 | $46,000 | $444,000 |
| Income before taxes | $41.5M | $76.4M | $102.5M | $108.6M | $170.6M | $177.9M | $150.5M | $191.5M | $134.6M | $138.6M |
| Income taxes | $30.1M | $34.3M | $38.7M | $39.3M | $54.1M | $53.3M | $50.0M | $65.3M | $72.1M | $38.5M |
| Net income | $10.8M | $42.0M | $63.8M | $69.3M | $116.5M | $124.7M | $100.5M | $126.2M | $62.5M | $100.0M |
| EBITDA | $82.1M | $98.9M | $123.1M | $129.0M | $192.4M | $199.0M | $169.2M | $205.2M | $148.6M | $152.1M |
| EPS (diluted) | $1.92 | $2.60 | $3.30 | $3.59 | $5.71 | $5.86 | $4.42 | $5.11 | $3.97 | $3.99 |
| Gross margin | 78.3% | 79.4% | 79.4% | 80.6% | 81.6% | 81.6% | 82.3% | 83.1% | 82.9% | 82.1% |
| Operating margin | 5.5% | 7.8% | 10.1% | 10.8% | 14.3% | 15.6% | 13.8% | 15.8% | 12.7% | 13.8% |
| Net margin | 1.2% | 4.9% | 6.9% | 6.9% | 9.8% | 11.0% | 9.5% | 10.6% | 6.0% | 9.9% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $223.3M | $250.2M | $226.2M | $213.7M | $235.8M | $249.5M | $213.6M | $200.2M | $212.9M | $227.8M | $221.1M | $213.4M |
| Cost of revenue | $48.3M | $59.4M | $49.4M | $48.8M | $57.9M | $60.8M | $42.6M | $42.8M | $44.1M | $46.2M | $45.2M | $45.8M |
| Gross profit | $174.9M | $190.8M | $176.8M | $164.9M | $177.9M | $188.8M | $171.1M | $157.4M | $168.7M | $181.6M | $175.9M | $167.6M |
| Research & development | — | — | — | — | — | — | $11.6M | — | — | — | $11.4M | — |
| Sales, general & admin | $82.3M | $88.3M | $78.1M | $85.9M | $81.9M | $91.4M | $73.3M | $61.3M | $150.9M | $64.3M | $58.7M | $63.3M |
| Total operating expenses | $194.9M | $176.9M | $159.5M | $163.6M | $161.2M | $173.1M | $162.9M | $141.8M | $150.9M | $156.9M | $151.6M | $150.0M |
| Operating income | −$20.0M | $13.9M | $17.2M | $1.2M | $16.7M | $15.7M | $8.2M | $15.6M | $17.8M | $24.7M | $24.2M | $17.6M |
| Interest income | $595,000 | $437,000 | $495,000 | $578,000 | $619,000 | $723,000 | $2.7M | $3.1M | $2.8M | $2.7M | $2.9M | $2.7M |
| Interest expense | $0 | $240,000 | $123,000 | $49,000 | $259,000 | $411,000 | $129,000 | $49,000 | $51,000 | $52,000 | $145,000 | $43,000 |
| Income before taxes | −$18.9M | $15.5M | $4.2M | $1.8M | $18.8M | $16.7M | $10.4M | $18.6M | $20.2M | $27.1M | $26.6M | $20.5M |
| Income taxes | $9.1M | $8.5M | $5.8M | $8.5M | $8.4M | $7.4M | $5.9M | $8.0M | $9.8M | $10.6M | $9.8M | $9.2M |
| Net income | −$21.4M | $7.5M | −$1.8M | −$6.5M | $9.7M | $9.4M | $4.5M | $10.6M | $10.4M | $16.5M | $16.8M | $11.3M |
| EBITDA | −$9.7M | $25.5M | $14.6M | $11.4M | $28.7M | $27.4M | $16.4M | $24.2M | $26.0M | $32.2M | $31.6M | $25.7M |
| EPS (diluted) | −$0.07 | $0.61 | $0.60 | −$0.15 | $0.74 | $0.73 | $0.64 | $0.56 | $0.54 | $0.86 | $0.87 | $0.59 |
| Gross margin | 78.3% | 76.2% | 78.2% | 77.2% | 75.4% | 75.6% | 80.1% | 78.6% | 79.3% | 79.7% | 79.5% | 78.5% |
| Operating margin | −9.0% | 5.5% | 7.6% | 0.6% | 7.1% | 6.3% | 3.8% | 7.8% | 8.4% | 10.8% | 11.0% | 8.3% |
| Net margin | −9.6% | 3.0% | −0.8% | −3.1% | 4.1% | 3.8% | 2.1% | 5.3% | 4.9% | 7.3% | 7.6% | 5.3% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in USNA's financial statements (latest annual report filed March 16, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
USNA financial results
In fiscal year 2025 (ended December 31, 2025), USANA Health Sciences reported revenue of $925.3 million, up 8.3% from the year before. It had net income of $10.8 million (down 74.4%), a net profit margin of 1.2%. Diluted earnings per share came to $1.92. Over five years revenue grew at an average rate of −4.0% a year.
See the USNA stock overview for the latest quote and news, or the USNA chart for price history and technical indicators.
USNA income statement FAQ
What is USANA Health Sciences's annual revenue?
USANA Health Sciences reported total revenue of $925.3 million for fiscal year 2025, which ended on December 31, 2025. That was up 8.3% from $854.5 million the previous year.
Is USANA Health Sciences profitable?
Yes. USANA Health Sciences reported net income of $10.8 million in fiscal 2025, a net profit margin of 1.2%; its operating margin was 5.5%.
What is USANA Health Sciences's gross margin?
USANA Health Sciences's gross margin was 78.3% in fiscal 2025: for every $100 of revenue, USANA Health Sciences kept $78 after the direct cost of its products and services.
How fast is USANA Health Sciences growing?
Revenue grew −4.0% a year on average over the last five fiscal years, from $1.1 billion to $925.3 million.
What are USANA Health Sciences's earnings per share?
USANA Health Sciences earned $1.92 per diluted share in fiscal 2025, compared with $2.60 a year earlier.
When will USANA Health Sciences report its next earnings?
USANA Health Sciences is expected to report results for the quarter ending September 30, 2026 on November 3, 2026 after the market closes.
When does USANA Health Sciences's fiscal year end?
USANA Health Sciences's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 16, 2026.